Related Experiment Video

Updated: Sep 10, 2025

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

6.0K

Glucagon-like peptide-1 receptor agonists and muscle mass effects

Alexandr Ceasovschih1, Andreea Asaftei1, Maria Giovanna Lupo2

  • 1Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, Iasi, Romania; 2nd Internal Medicine Clinic, 'Sf. Spiridon' Clinical Emergency Hospital, Iasi, Romania.

Pharmacological Research
|August 26, 2025
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively treat obesity but may reduce muscle mass. Strategies are needed to preserve muscle health during GLP-1 RA therapy.

Area of Science:

  • Endocrinology
  • Metabolic Disease
  • Geriatrics

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for obesity management.
  • Emerging evidence suggests GLP-1 RAs may negatively impact skeletal muscle mass.

Purpose of the Study:

  • To review the effects of GLP-1 RAs on body composition.
  • To explore mechanisms of GLP-1 RA-induced muscle wasting.
  • To propose strategies for mitigating muscle loss.

Main Methods:

  • Literature review of clinical and paraclinical studies.
  • Analysis of pathophysiological mechanisms.
  • Synthesis of evidence-based management strategies.

Main Results:

  • GLP-1 RAs demonstrate significant weight loss and metabolic improvements.
  • Potential for unintended reduction in skeletal muscle mass observed.
  • Risk is higher in older or frail individuals.

Conclusions:

  • GLP-1 RAs are crucial for obesity treatment.
  • Preserving muscle mass is essential for functional status and quality of life.
  • Early risk identification and management are key for optimizing GLP-1 RA therapy.
Keywords:
GLP-1 receptor agonistsMuscle massObesitySarcopeniaSkeletal muscle lossWeight loss

More Related Videos

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.2K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.7K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256